End results of thoracolumbar sympathectomy for advanced essential hypertension

California Medicine
|April 1, 1949
PubMed

Insights

Thoracolumbar sympathectomy for essential hypertension showed a 16% mortality. More extensive procedures yielded better results but increased mortality, suggesting a need for further data to balance outcomes and risks.

Area of Science:

  • Cardiovascular Surgery
  • Neurosurgery
  • Vascular Surgery

Background:

  • Essential hypertension is a significant health concern, often requiring surgical intervention in advanced stages.
  • The study period (1942-1948) predates many modern antihypertensive therapies.
  • Patient selection for surgery was guided by specific clinical judgment criteria.

Purpose of the Study:

  • To evaluate the outcomes and mortality associated with thoracolumbar sympathectomy for essential hypertension.
  • To compare the efficacy and risks of different extents of sympathectomy.
  • To determine the role of sympathectomy in managing advanced hypertensive vascular disease.

Main Methods:

  • Analysis of 473 patients undergoing thoracolumbar sympathectomy between 1942 and 1948.
  • Comparison of outcomes between limited and more extensive sympathectomy procedures (Smithwick procedure variations).
  • Inclusion of total sympathectomies involving the stellate ganglion in later cases.

Main Results:

  • Overall mortality was 16% (79 deaths), with 8% in-hospital mortality (38 deaths).
  • Leading causes of in-hospital death: cerebral accident, cardiac failure, renal insufficiency.
  • Leading causes of out-of-hospital death: cardiac failure, cerebral accident, renal insufficiency.
  • More extensive sympathectomies showed improved results but higher mortality rates.

Conclusions:

  • Thoracolumbar sympathectomy has a role in treating hypertensive vascular disease.
  • In advanced cases, the procedure primarily offers palliative benefits.
  • Further data is required to definitively conclude if complete sympathectomy is superior to less extensive procedures, considering mortality risks.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Disorders of the Autonomic Nervous System01:18

Disorders of the Autonomic Nervous System

The autonomic nervous system (ANS) is an intricate network of nerves that controls functions such as the regulation of heart rate, digestion, and blood pressure regulation. When this system malfunctions, it can lead to various disorders that affect multiple bodily functions. One common feature of many autonomic disorders is the involvement of smooth blood vessels, which play a crucial role in regulating blood flow throughout the body.
Raynaud's disease, also known as Raynaud's phenomenon, is a...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...